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Preserving Survival Time (RPSFT) model were used as secondary analyses. The
Inverse Probability of Censoring Weights (IPCW) method and the Cox model using
treatment as a time-dependent covariate were used as sensitivity analyses.
RESULTS: Overall, 71% of patients randomized to dexamethasone crossed over to
bortezomib. The primary analysis led to a hazard ratio of 0.59 (95%CI: [0.32,0.86]) for
bortezomib versus dexamethasone, compared to 0.77 (95%CI: [0.61,0.97]) using the
ITT approach. The results of the secondary analyses were consistent with the
primary analysis. The IPCW provided results, which were very sensitive to the
choice of the time interval. Lastly, the Cox model with treatment as a time-depen-
dent variable resulted in a counter-intuitive higher hazard ratio than the ITT anal-
ysis, consistent with results from simulation studies indicating this approach is
biased.CONCLUSIONS:Adjusting for crossover led to a decrease of the hazard ratio
from 0.77 to 0.59, and resulted in wider confidence intervals than the ITT analysis.
Additional analyses are required to assess the performance of the IPCW method
compared to the IPE algorithm and the RPSFT model under different scenarios.
Cancer – Cost Studies
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BUDGET IMPACT MODEL FOR RARE CANCER TREATMENT: CASE IN POINT
CUTANEOUS T-CELL LYMPHOMA
Aggarwal S
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OBJECTIVES: Develop budget impact model to forecast total cost of treatment for
cutaneous T-cell lymphoma (CTCL) for US public and private payer.METHODS:The
clinical efficacy and safety data were obtained from the published pivotal study
results. Costs of adverse events were estimated based on claims database analysis,
AHRQ’s HCUP and CMS Medicare 2009 databases. Drug cost was estimated based
on 2011 AWP price. Epidemiology data were obtained from NCI-SEER and CDC
databases. A budget impact model was implemented over a period of five years,
based on a stable population and on different penetration and substitution rates of
newly approved therapy. Model was developed in excel based format. Blinded
Model design and outputs were tested with payers and KOLs. RESULTS: For rare
cancers such as CTCL, the budget impact of treatment with targeted cancer therapies
is in the range of $460,000-$530,000 per 1 million covered lives. The per patient per
member (PPPM) budget impact of this treatment is 46-53 cents. Medical cost offsets
were estimated but were insignificant compared to total cost of treatment. US payers
rated PPPM output as the one of the most important relevant outputs of model.
CONCLUSIONS: This budget impact model shows that new treatments for rare
forms of cancer are likely to have minimal budget impact on payers. PPPM based
outputs are more relevant to payers, than per patient treatment costs. However, an
emerging concern is the total budget impact of all therapies indicated for ultra-
orphan disorders, which might be an important consideration for future models.
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OBJECTIVES:Digital mammography is costlier than screen film mammography but
presents benefits at the technological and logistic level. The aim of this study was
to analyze the budget impact and the health benefits of the introduction of digital
mammography in a population-based breast cancer screening program.
METHODS: A discrete-event simulation model was implemented including the
processes under a breast cancer screening program and the natural history of
breast cancer. The screening events included: invitation (biennial) of the target
population (women aged 50-69 years), participation, screening test, confirmatory
tests after a positive mammography result, cancer diagnosis and treatment. Nat-
ural history of breast cancer included the following health states: no cancer, pre-
clinical (non symptomatic) cancer, clinical (or symptomatic) cancer and death.
Digital and analogical mammography had the same sensitivity, but different spec-
ificities were applied according to type of mammography and also initial or suc-
cessive screening. Results were collected during a 20-year screening scenario.
RESULTS: A total of 90,575 women were screened under both techniques during
the simulated 20 years. This population resulted in more than 262,500 screening
mammograms. The recall rate was 5.9% under digital mammography and 6.4%
under analogical mammography, while the numbers of confirmatory tests needed
were 23,728 and 32,697, respectively. The cancer detection rate was 0.7% for both
techniques. Digital mammography saved 1.909.167 euros in additional tests, while
it was 1.026.807 euros more expensive in screening mammograms and presented
similar costs of treatments. CONCLUSIONS: Results suggest that, although popu-
lation-based breast cancer screening with digital mammography is costlier in
terms of screening mammographies, it saves money in terms of additional tests
needed. The health benefits are similar to those of conventional analogical mam-
mography, but it reduces the number of additional tests needed, which represent a
clear benefit to participating women.
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OBJECTIVES: The addition of MEPACT as an add-on treatment to adjuvant chemo-
therapy in the treatment of high-grade non-metastatic osteosarcoma after macro-
scopically complete surgical resection has been shown to significantly increase
overall survival of young patients. This study assessed the costs (drug and admin-
istration) and the long-term financial impact on the UK (UK) government of intro-
ducing MEPACT. METHODS: Based on the cost of MEPACT and using survival rates
derived from a clinical trial, we projected the net budgetary impact of MEPACT
compared to no MEPACT. Further, we modelled the net tax contribution to the state
of a surviving patient over a lifetime by subtracting direct government transfers
that are made to the individual (child benefit, education etc) from the individual’s
gross tax contribution based on average anticipated earnings. RESULTS: Using UK
incidence rates of osteosarcoma the model estimated approximately 54 newly di-
agnosed non-metastatic cases per year. Assuming that 38 doses of MEPACT (cal-
culated from trial data) are added to the treatment regimen of 50% of patients at a
cost of £91,189 , the expected 1-year cost would be UK £3,972k compared with
£1,450k had all patients been treated without MEPACT. Administration costs ac-
counted for 3% of total costs. The lifetime discounted value of net taxes from a 14
year old patient treated with MEPACT is £79,000. The breakeven age, defined as the
point at which the net tax contribution becomes greater than zero, is approxi-
mately 41 years. CONCLUSIONS: The additional budget impact due to MEPACT is
mainly due to the cost of the drug. From the tax calculations, we conclude that
investment in MEPACT does not negatively impact the long run fiscal budget of the
UK government. Conversely, by taking a broader government perspective over an
average lifetime, a surviving patient returns a positive net value to the State.
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OBJECTIVES: To evaluate the budget impact of nilotinib for newly diagnosed pa-
tients with chronic myeloid leukemia (CML) for the health care system in Bulgaria.
METHODS: Current standard of therapy (imatinib) is compared with the newly
authorized for sale nilotinib and dasatinib used as a first line therapy. Cost of yearly
pharmacotherapy and adverse drug reactions management have been calculated
for 3 years for different proportions of newly diagnosed patients with CML in
chronic phase. The exchange rate is 1 BGN  0.51 EUR. RESULTS: Clinical studies
shows significant benefits from nilotinib but the question remains if it is worth the
cost of therapy. Calculation of the yearly pharmacotherapy cost per 100 patients
arranges the medicines in monetary value order as follows: 5,398,092 BGN for ima-
tinib, 6,564,681 BGN for nilotinib, and 8,365,872 BGN for dasatinib. Weighed cost by
the probability of appearing of the ADR is 733.26 BGN for imatinib, 509.75 for nilo-
tininb, and 1,010.29 BGN for dasatinib. The relative share of patients treated with
nilotinib in first line is 12% for the first year, 32% for the second, and 38% for the
third year. The introduction of nilotinib will change the budget for all patients with
CML to 6,895,316 in comparison with 6,725,246 BGN before the introduction, to
7,177,671 BGN in the second year, and to 7,262,378 BGN in the third year. Thus the
over all increase for the observed 3 years will be within 179,044 BGN.
CONCLUSIONS: The introduction of nilotinib as first line therapy for patients with
newly diagnosed CML will lead to relatively small increase in the health care bud-
get in Bulgaria compared to the clinical benefit in terms of achievement of deeper
response, improvement of overall survival and less disease progression.
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OBJECTIVES: Capecitabine (C) is approved in Brazil for the treatment of breast
cancer (BC), 2nd or subsequent lines. In the private sector, it’s not often used, due
to the fact that health insurance plans (HI) do not offer coverage for oral (PO)
chemotherapy (CHEMO), only for intravenous (IV). Our aim was to determine if the
use of C could spare costs if adopted by HI. METHODS: We searched Evidencias
Database for BC patients eligible for the use of C, in the year of 2008. This database
has information from over 2 million of users of 14 HI. We identified the IV CHEMO
actually used and the costs paid. Then, based on the data of each individual patient
and in the length of use of CHEMO, we calculated the associated costs in a scenario
where C replaced the IV CHEMO used. Also, we performed some sensitivity analysis
based on different percentages of substitutions of IV by PO chemo. We considered
only the prices of drugs. RESULTS: We found 518 BC patients eligible for C use.
These patients received 3581 cycles of chemotherapy (Paclitaxel, Docetaxel, Gem-
citabine, Vinorelbine, Doxorubicin). The total cost for these treatments were US$ 5
364 000. If C replaced 100% of the IV CHEMO, the total cost would drop to
US$2,078,000, 62% smaller than the IV alternative. In a simulation, where 60% of the
patients would use the IV option and 40% would use C, the total cost would also be
smaller: US$4,050,000, 25% smaller than when IV route is used exclusively.
CONCLUSIONS: The adoption of C by HI in Brazil is cost-saving for BC patients.
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BUDGETARY IMPACT OF ADOPTION OF ERLOTINIB FOR LUNG CANCER IN THE
PRIVATE HEALTH INSURANCE MARKET IN BRAZIL: A REAL WORLD DATA
ANALYSIS
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OBJECTIVES: In Brazil, health insurance plans (HI) must pay for anticancer intra-
venous (IV) chemotherapy (CHEMO) but not for those taken by mouth (PO). Erlotinib
(E) is a PO CHEMO used to treat lung cancer 2nd or 3rd line. Our aim was to establish
the budgetary impact of the adoption of E, when compared to the IV competitors
docetaxel (D) and pemetrexed (P) for the HI in Brazil. METHODS: We searched
Evidencias Database for patients eligible for the use of E, in the year of 2008. This
database has information from 2 million of users of 14 HI. Then, we calculated the
costs of the IV chemo actually used. A simulation of the costs if E were adopted was
carried out. Many different sensitivity analyses were performed, according to the
line of treatment in which E was administered and the proportion changing from IV
to the PO option. RESULTS: We found 285 records of patients that were suitable for
the use of E. The cost of IV CHEMO was US$2,293,000. If E replaced the treatment for
all patients, the cost would be reduced to US$1,067,000, resulting in a economy of
US$1,222,000 (54%) of the total. If instead of replacing the IV option, E was used as
an additional line of treatment, an increase of US$635,000 in total costs would
occur. In a sensitivity analysis, that can reflect the practice, where 50% of the
patients would receive E instead of P or D in 2nd line, and 30% would receive E in 3rd
line, the adoption of E would result in an economy of US$295,000. CONCLUSIONS:
The adoption of E for the treatment of lung cancer in Brazil can be cost-saving for
HI.
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OBJECTIVES: To examine variation in real world health care utilization (HCU) and
costs associated with management of brain metastasis (BrMts) by primary malig-
nancy type. METHODS: A retrospective analysis utilized claims-data from a na-
tional health insurer, identifying patients18 yrs with2 claims7 days apart for
BrMets (ICD-9 198.3x) from January 2004 to April 2010. The index date was the date
of the first BrMets claim. Continuous enrollment (CE) in the health plan for 6
months before (baseline) and 1 month after (follow-up) index date was required;1
month follow-up was permitted if due to death. Excluding primary brain tumors,
baseline CE data (1993 to the index date) was examined to identify the initial pri-
mary malignancy. HCU (inpatient stays, office, outpatient and ER visits) and all-
cause per-patient per-month (PPPM) costs were examined. RESULTS: A total of
1031 lung and 395 breast cancer patients, and 93 with melanoma were included.
Baseline Charlson comorbidity score was not significantly different. Mean age at
BrRMets diagnosis was highest for lung (60yr) compared to breast cancer (55yr) and
melanoma (56yr)[p-value0.01]. Rates of HCU (events/person-month) were signif-
icantly different for melanoma, breast and lung cancer patients: 0.28 versus 0.17
and 0.24 for inpatient stays; 3.16 versus 3.87 and 3.94 for office visits; 2.84 vs. 2.69
and 2.80 for outpatient visits [p-value0.01]. Total costs PPPM were highest for
melanoma ($21,373) compared to breast ($17,933) and lung cancer ($15,199) [p-
value0.001]. Inpatient costs PPPM represented the largest portion of medical costs
(44%-50%), but were not significantly different across cohorts: melanoma ($9397),
breast ($8781) and lung cancer ($7628). Pharmacy costs PPPM were highest among
melanoma ($1555) then breast ($737) and lung cancer ($720) [p-value 0.001].
CONCLUSIONS: Variation was observed in HCU and costs among BrMets patients
based on initial primary tumor type. Analyses of cost studies on BrMets patients
need to take this into consideration.
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OBJECTIVES: To estimate direct costs associated to grades 3-4 adverse events (AEs)
management treatment of metastatic renal cell carcinoma (mRCC) with targeted
therapies (sorafenib, sunitinib, pazopanib, bevacizumab, everolimus and tem-
sirolimus) and to perform a comparative analysis from public and private health-
care perspectives, in Brazil. METHODS: A systematic literature review was con-
ducted to identify grades 3-4 AEs related to targeted therapies. To obtain direct
costs related to AEs management, procedures were created from national guide-
lines and expert validation. Total cost for each drug was calculated, considering a
six-month time horizon. Only direct medical costs were considered, expressed in
2011 Brazilian reals (BRL). Unit costs were obtained from Brazilian official lists. As
no head-to-head trials were found, indirect comparison in second-line targeted
therapy was performed according to NCCN guideline for everolimus (grade 1 rec-
ommendation) versus sorafenib and sunitinib (grade 2A) and temsirolimus (grade
2B). Bevacizumab (grade 2B) was excluded as data was available only for the asso-
ciation with IFN. In the base case, grades 3-4 incidence rates were obtained from
phase III clinical trials and varied in sensitivity analysis based on results obtained
in meta-analyses or observational studies. RESULTS: When compared to NCCN 2A
recommendation grade for second-line targeted therapy, everolimus is cost-saving
in base case and sensitivity analysis: versus sorafenib, there are savings ranging
from 5BRL to 717BRL and from 96BRL to 5841BRL in public and private perspectives,
respectively; versus sunitinib, savings vary from 153BRL to 681BRL and from
1778BRL to 5136BRL in public and private perspectives, respectively. Everolimus
was cost-saving due to easily manageable AEs and their frequencies.
CONCLUSIONS: Considering grades 1 and 2 NCCN recommendation for mRCC sec-
ond-line targeted therapies, everolimus represents the highest quality of evidence
and is also considered the lowest cost option for the management of associated AEs
from public and private healthcare perspectives, in Brazil.
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OBJECTIVES: Assessing the adverse events costs of comparable regimens
(sunitinib vs bevacizumab) in context of budget impact analysis in Croatian setting.
METHODS: Authors have assessed costs and outcomes of bevacizumab and
sunitinib via systematic review, performed in January 2011. Survival rates, inci-
dence and prevalence was assessed via Croatian National Cancer Registry, and the
model was verified with Monte Carlo simulations. Direct drug, adverse events and
treatment costs were calculated in kuna/per patient yearly according to price list-
ings of National Institute for Health Insurance. Local data was verified with struc-
tured interviews gathered with Croatian oncologists (N6) involved in this indica-
tion in their daily practice. Focus of the analysis was the drug cost and the adverse
events treatment cost. RESULTS: Sunitinib has showed costly side effects such as
neutropenia, trombocitopenia, hypothiroidism and cardiovascular complications.
The cost of adverse events (aforementioned) for sunitinib per patient yearly is 3.904
HRK (535 EUR), whereas for bevacizumab is 1.404 HRK (192 EUR). Bevacizumab
demonstrated significantly lower adverse events costs than sunitinib. Overall bud-
get impact (from payers perspective) when bevacizumab is introduced equals
-29.753,52 HRK (-4075 EUR) of savings yearly per patient.CONCLUSIONS:At current
costs, head to head drug price comparison demonstrates that bevacizumab is less
costly, demonstrating dominant ability to reduce costs due to less frequent and
less costly adverse events, whereas in budget impact context introducing bevaci-
zumab brings savings.
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OBJECTIVES: Spaepen et al. (The Oncologist 2008;13:596–607) published a cost
analysis comparing darbepoetin-alfa (DARB), epoetin-alfa (EPO-A) and epoetin-
beta (EPO-B) in the treatment of chemotherapy-induced anaemia in 2393 patients.
Data were derived from the IMS Hospital Disease Database, a longitudinal database
in secondary care unique to Belgium. The objectives of this study were to assess the
applicability of that analysis in the Spanish setting, and to evaluate differences in
cost between ESAs in Spain. METHODS: To adapt the Belgian data for Spain, dis-
crepancies in epidemiology and treatment patterns were examined, and costs were
replaced with Spanish-specific unit costs. Adjusting for tumour-specific incidence
and chemotherapy use, costs were analyzed using a mixed-effects model stratify-
ing for propensity score quintiles as in Spaepen 2008. Data sources included Euro-
stat, national cancer registries, IMS sales data, treatment guidelines, and reim-
bursement guidelines and lists. RESULTS: The Spanish and Belgian populations
were similar in terms of age, gender, ESA use and blood transfusions. Adjusting for
chemotherapy use and the relative weight (incidence Spain/ incidence Belgium) of
four pre-specified cancer types [haematological (1.2094), lung (0.6716), female
breast (0.5654) and female genital (0.9589)], total costs (meanSE) with DARB were
26% lower compared with EPO-A (p0.0001) and 20% lower compared with EPO-B
(p0.0019). Anaemia-related costs were 29% and 17% lower in DARB patients than
in EPO-A (p0.0001) and EPO-B (p0.0226) respectively. The mean duration of treat-
ment was 40.632.39 days for DARB; 53.591.25 for EPO-A and 52.392.54 for
EPO-B. CONCLUSIONS: By using published epidemiologic and treatment pattern
data, it was possible to adapt the Belgian Hospital database to the Spanish popu-
lation. Total and anaemia-related costs were lowest in patients receiving DARB
compared with EPO-A or EPO-B. These findings are consistent with those from the
Belgian analysis.
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OBJECTIVES: Spaepen et al. (the Oncologist 2008;13:596–607) published a cost-
analysis comparing darbepoetin-alfa (DARB), epoetin-alfa (EPO-A) and epoetin-
beta (EPO-B) in the treatment of chemotherapy-induced anaemia, using propensity
score matching. The study was performed using IMS Hospital Disease Database
(2003-2005, a longitudinal database unique to Belgium containing individual pa-
tient/admission-level data on diagnoses, procedures, and pharmaceuticals. Given
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